# A French Study to Evaluate the Usefulness of an Implantable Continuous Glucose Monitoring (CGM) Sensor to Improve Glycemic Control in Participants With Diabetes Mellitus

> **NCT03445065** · NA · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 239 (actual)

## Conditions studied

- Diabetes Mellitus

## Interventions

- **DEVICE:** Eversense XL CGM System
- **DEVICE:** Usual SMBG or FGM device used by participants

## Key facts

- **NCT ID:** NCT03445065
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-28
- **Primary completion:** 2020-08-20
- **Final completion:** 2020-08-20
- **Target enrollment:** 239 (ACTUAL)
- **Last updated:** 2021-09-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03445065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03445065, "A French Study to Evaluate the Usefulness of an Implantable Continuous Glucose Monitoring (CGM) Sensor to Improve Glycemic Control in Participants With Diabetes Mellitus". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03445065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*